IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Zairen Sin

Serial No.: 10/717,665

Group Art Unit: 1644

Filed: November 21, 2003

Examiner: Maher M. Haddad

For: RGULATED ANGIOGENESIS GENES POLYPEPTIDES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes		Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:		
		within three months of the filing date of a national application other than a CPA under § 1.53(d);		
		within three months of the actual filing date of the national phase of a PCT application; OR		
	\boxtimes	before the mailing of a first substantive office action (including after filing of an RCE).		
	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the perspecified in 37 C.F.R. § 1.97(b), but before the mailing date of:			
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and		

DOCKET NO.: ORIGEN-0009-D01

		is acco	ompanied by:		
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR		
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).		
		nder 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing te of the following actions which have not been withdrawn:			
		a final	action under 37 C.F.R. § 1.113;		
		termin	nation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);		
		OR a ı	notice of allowance under 37 C.F.R. § 1.311;		
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:		
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).		
Stater	nents U	nder 37	C.F.R. 1.97(e)		
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or		
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.		
Cited	Materia	<u>ls</u>			
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 12 ancestor application Serial No, on Form 892 by the Examiner and/or Fo. 1449 by the applicant; see 37 C.F.R. § 1.98(d).			
		-	s of materials listed but not attached were cited in an international search dated		
		Not re	quired by 37 CFR § 1.98.		
	× ,	Copies	s of the materials listed are attached.		

Non-Eng	dish Language References		
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s). A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:		
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art O = non-written disclosure P = intercalated document T = document cited to understand the theory or principle underlying the invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D = cited in the application L = cited for another reason & = publication of member of same patent family 		
	Translation of other relevant information on foreign search report		
	[insert necessary translation here]		
Other Inf	<u>Formation</u>		
	of Fees Due (If Any): check for \$ covering the fee identified above is attached.		
P	lease charge to Deposit Account No. 13-3402 \$ for the fee identified above.		

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Richard M. Lebovitz, Reg. No. 37,067 Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: OGRIGEN-0009-D01

Date: February 9, 2006

RML:jmj

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00) =

Approved for use through 10/31/2002. OMB 0651-0031
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1996, go persons are requ Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

ART	Complete if Known			
Application Number	10/717,665			
Filing Date	November 21, 2003			
First Named Inventor	Zairen Sun			
Group Art Unit	1644			
Examiner Name	Maher M. Haddad			
Attorney Docket Number	ORIGEN-0009-D01			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	,	Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences; Mammalian Gene Collection (MGC) Program Team; Proc. Natl. Acad.; December 24, 2002 vol. 99, No. 26, pp. 16899-16903	
		NP-705835	
		AA018732	
		XP-881296	
		XP-852847	
		AAN28956	
		BC041709	
		AAN28956	
		BLAST Search of nr using ANH0757 (only pages 1-105 provided)	
		·	
			-

Examiner	Date	
Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.